Hemogenyx Pharmaceuticals (LSE:HEMO) Short Percentage of Float


LSE:HEMO Hemogenyx Pharmaceuticals PLC LSE:HEMO
31 GF Score
Price £7.70
! 2 Warning Signs
View Full Analysis

What is Hemogenyx Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LSE:HEMO vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's Short Percentage of Float falls into.


LSE:HEMO
31GF Score
Hemogenyx Pharmaceuticals PLC LSE:HEMO
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemogenyx Pharmaceuticals Business Description

Address 6 Heddon Street, London, GBR, W1B 4BT
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
31GF Score

Get the complete analysis for LSE:HEMO

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£7.70
Price